Intravascular imaging guidance in complex PCI: a meta-analysis of randomized trials across complex lesion subsets.

Int J CardiolOct 8, 2026 (epub)
Clinical ResearchCardiology

Mattia Basile, Javier Gómez Herrero, Alejandro Lara García et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis pooled randomized trials comparing intravascular imaging (IVI)-guided with angiography-guided PCI in patients with trial-defined complex PCI or extractable complex-lesion cohorts. Across 15 trials and 11,557 patients, IVI guidance was associated with lower target vessel failure (TVF; RR, 0.70; 95% confidence interval [CI], 0.56-0.86; number needed to treat, 26 [95% CI, 18-55]). Repeat revascularization and stent thrombosis were also reduced. Lesion-subset estimates favored IVI but were not significant in the primary analyses; all became significant after excluding IVUS-CHIP.

Key findings

  • IVI guidance reduced TVF (RR, 0.70; 95% CI, 0.56-0.86; number needed to treat, 26 [95% CI, 18-55]).
  • Target vessel revascularization (RR, 0.68; 95% CI, 0.53-0.87) and target lesion revascularization (RR, 0.67; 95% CI, 0.52-0.85) were lower with IVI.
  • Stent thrombosis was reduced with IVI (RR, 0.42; 95% CI, 0.24-0.73); all-cause mortality was not reduced.
  • Effects were similar for intravascular ultrasound and optical coherence tomography (interaction p = 0.93).

Why it matters

Complex PCI carries clinically important risks of vessel failure and repeat procedures. This pooled randomized-trial evidence suggests that imaging guidance can reduce TVF and several related complications compared with angiography guidance. The findings support considering IVI as a procedural strategy in complex PCI, while the uncertain lesion-specific results and absence of an all-cause mortality benefit temper conclusions about which patients benefit most.

What to keep in mind

Lesion-specific estimates were not significant in the primary analyses and became significant only after excluding IVUS-CHIP. The cardiovascular mortality finding was borderline, and lesion-subset effects were described as exploratory.

Source

Published in Int J Cardiol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.